Podcasts about recurrent

In this episode of The Egg Whisperer Show, Dr. Jenna Turocy is joining me to talk about new treatment options for recurrent implantation failure. Recurrent implantation failure (RIF) is determined when embryos of good quality fail to implant following several in vitro fertilization (IVF) treatment cycles. The good news is that there is treatment for this, and Dr. Turocy has been researching it. The types of treatments that Dr. Jenna has studied include:

Urinary tract infections are one of the most common health issues women experience, yet there's still so much confusion about what they are, why they happen, and how they're different from yeast infections and other vaginal conditions. In this episode of Ask Dr. A, Dr. Aliabadi breaks down the anatomy behind UTIs, explains the difference between bladder infections and kidney infections, and shares the symptoms every woman should know.Dr. Aliabadi also dives into why some women seem to get recurrent UTIs while others never experience them, covering the roles of hydration, sex, genetics, hormones, menopause, and the vaginal microbiome. She explains how bacteria causes infection, why urine cultures are essential for an accurate diagnosis, and the common mistakes that can lead to repeated infections.Plus, you'll learn evidence-based prevention strategies, including the truth about cranberry supplements, D-mannose, vaginal estrogen, probiotics, and whether peeing after sex actually helps. If you've ever wondered why UTIs keep coming back, or how to lower your risk, this episode is packed with practical information every woman should know.Subscribe to SHE MD Podcast for expert tips on PMOS, endometriosis, fertility, hormonal balance, mental health, and more. Share with friends and visit SHE MD website and Ovii for research-backed resources, holistic health strategies, and expert guidance on women's health and well-being.SponsorsMidi: Ready to feel your best and write your second act script? Visit JoinMidi.com today to book your personalized, insurance-covered virtual visit. Peloton: Let yourself run, lift, sculpt, push and GO. Explore the new Peloton Cross Training Tread+ at onepeloton.comMyriad: List GetMyRisk.com to learn more about hereditary cancer testing and how you can use Myriad's virtual care option for fast, at-home testing - no office visit required. Talkiatry: Head to Talkiatry.com/shemd and complete the short assessment to get matched with an in-network psychiatrist in just a few minutes.Transcendental Meditation: Curious about Transcendental Meditation? Find a certified teacher near you and begin your journey today. Go to TM.org/SheMDWhat You'll LearnThe difference between UTIs, bladder infections, kidney infections, and yeast infectionsHow bacteria enters the urinary tract and causes infectionCommon UTI symptoms and warning signs you shouldn't ignoreWhy some women are more prone to recurring infectionsThe role of hydration, sex, and vaginal health in UTI preventionHow menopause and declining estrogen affect urinary tract healthWhen a urine culture is necessary and why it mattersThe truth about cranberry supplements, D-mannose, and other prevention strategiesWhy recurrent UTIs may require a deeper investigationKey Timestamps00:00 Welcome to She MD Podcast00:46 UTI, Yeast infection, Bladder infection, and Kidney infection07:12 E.coli and how you get them in the urethra13:09 How is the test called?19:45 What can a woman do for these infections?29:13 What kind of treatment will help with the infection?37:15 Vaginal Estrogen Treatment 45:18 How do you address the bacteria?50:20 How much is too much?51:40 Let's address some myths 53:33 Final WordsKey TakeawaysUTIs and yeast infections are completely different conditions that affect different parts of the body.Most UTIs begin as bladder infections caused by bacteria entering the urethra.Early diagnosis and treatment can help prevent serious kidney infections.Hydration, urinating after sex, and avoiding prolonged urine retention can reduce risk.Vaginal microbiome health plays a major role in preventing recurrent UTIs.Menopause-related estrogen loss can increase susceptibility to urinary tract infections.A urine culture is the best way to confirm whether symptoms are truly caused by a UTI.Cranberry extract and D-mannose may help prevent recurrent infections but are not treatments for active UTIs.Recurrent infections should prompt an evaluation of underlying causes rather than repeated rounds of antibiotics.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Contributor: Aaron Lessen, MD Educational Pearls:   UTIs are commonly seen in older women We often see them taking long-term prophylactic antibiotics because of common recurrence. Around 20-30% of older women who develop a UTI have a recurrence due to either diagnostic failure, treatment failure or non-compliance with treatment.  UTI signs and symptoms Burning sensation when urinating Strong urge to urinate Urinating often and passing small amounts of urine.  Pelvic pain    There are currently more guidelines and studies on treatments to prevent these recurrent UTIs in women that we can start in the Emergency Department. Vaginal estrogen has been shown to significantly reduce this issue of recurrence. Very simple prescriptions can be prescribed in the ED It has little systemic absorption and is generally very safe and effective.   References Wells BA, De EJB, Visingardi J, Feustel PJ. IP15-36 IMPACT OF VAGINAL ESTROGEN ON SERIOUS ADVERSE OUTCOMES IN POSTMENOPAUSAL WOMEN WITH RECURRENT URINARY TRACT INFECTIONS: A RETROSPECTIVE STUDY. Journal of Urology [Internet]. 2025 May 1;213(5S):e778. Available from: https://doi.org/10.1097/01.JU.0001109984.67114.74.36 Ackerman AL, Bradley M, D'Anci KE, Hickling D, Kim SK, Kirkby E. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004723 Kaufman MR, Ackerman LA, Amin KA, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 0(0). doi:10.1097/JU.0000000000004589 Meister MR, Wang C, Lowder JL, Mysorekar IU. Vaginal Estrogen Therapy Is Associated With Decreased Inflammatory Response in Postmenopausal Women With Recurrent Urinary Tract Infections. Female Pelvic Med Reconstr Surg. 2021 Jan 1;27(1):e39-e44. doi: 10.1097/SPV.0000000000000790. PMID: 31725016; PMCID: PMC7737516. Nazarko L. Recurrent lower urinary tract infection in older women [Internet]. Urology & Continence Care Today. Available from: https://www.ucc-today.com/journals/issue/launch-edition/article/recurrent-lower-urinary-tract-infection-in-older-women-ucct   Summarized by Aaryn David & Ahmed Abdel-Hafiz | Edited by Aaryn David & Ahmed Abdel-Hafiz, NREMT-P   Donate: https://emergencymedicalminute.org/donate/   Join our mailing list: http://eepurl.com/c9ouHf

Today on the podcast I am sharing a story that will speak straight to your soul.And a story that will remind you just how strong women can be.My guest today went through years of TTC and multiple losses. And just over a year ago, when she finally finally got the 2 pink lines she'd been waiting for again, she sadly lost her baby a few weeks later.  But the grief of this loss could not have prepared her for what came next.This is a conversation about miracles, resilience and navigating the depths of grief while you're still trying to bring your baby home.Thanks for being here on Your Journey to Fertility! When you finish listening, I'd love to hear your biggest takeaway from today's episode. Take a screenshot of you listening on your device, share it to your Instagram stories and tag me @jen.elementpilatesyoga If you're trying to conceive, I have lots of resources to support you:To grab a copy of my Free Fertility Yoga Guide, click here:To learn more about In Your Element - The Fertility Yoga Experience click here and start using so many of the practices I speak about for yourself.This program is a guided way to: Sync with your cycle & synchronize your hormonesIncrease success rates through proven, scientific methodsRegulate your nervous system & make every part of this journey feel easier

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Today, we're speaking to Dr Tori Ford, a qualitative researcher based at the Nuffield Department of Primary Care Health Sciences at the University of Oxford.Title of papers: ‘Accumulative Experiences: Navigating Healthcare for Recurrent Vulvovaginal Thrush from Patient and Clinician Perspectives' and ‘It's not just thrush, it's recurrent thrush': Patient and Clinician Perspectives on Diagnosing Recurrent Vulvovaginal Candidiasis'.Available at: https://doi.org/10.3399/BJGP.2025.0437 and https://doi.org/10.3399/BJGP.2025.0531TranscriptThis transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.Speaker A00:00:01.280 - 00:01:15.200Hi, and welcome to BJGP Interviews. I'm Nada Khan and I'm one of the associate editors of the journal. Thanks again for listening to this podcast today.In today's episode, we're speaking to Dr. Tori Ford, who is a qualitative researcher based at the Nuffield Department of Primary Care Health Sciences at the University of Oxford. We're going to talk today about two linked papers that she and her team have published here in the bjgp.The first one is titled Accumulative Navigating Healthcare for Recurrent Vulvovaginal Thrush from Patient and Clinician Perspectives. And the second paper is it's not just thrush, it's recurrent thrush.Patient and Clinician Perspectives on Diagnosing Recurrent Vulva Vaginal Candidiasis. So, Tori, thanks very much for joining us here today.And this might come from a slightly unscientific perspective, but my feeling is that I'm seeing a lot more recurrent thrush in practice. And we know that it's incredibly common. I think, despite that, it's not something we hear discussed very often in primary care research.So my first question is, what made you want to study it?Speaker B00:01:15.520 - 00:01:54.060So, like you say, recurrent thrush is an increasingly common condition. We know that 1.2 million women in the UK live with it, 6% of people globally, and I just happen to have been one of them.So my paper came out of lived experience of living with recurrent thrush over many years and having a diagnostic journey of, you know, seeing different healthcare professionals looking for answers. And like you say, those feelings of shame and stigma that keep you feeling alone were all too familiar for me.So that's what actually led me into starting my PhD, looking at recurrent thrush and then wanting to hear other patient experiences as well.Speaker A00:01:54.460 - 00:02:22.220And we're looking at two of your papers here that were published in the bjgp, and they're both looking at the patient and the clinician perspective.And one thing that comes through really strongly in both papers is that recurrent thrush is often treated as if it's just repeated acute episodes rather than a condition in its own right. Why do you think that that distinction matters to patients and probably to clinicians as well, or should do?Speaker B00:02:22.380 - 00:03:55.420I think when we hear about thrush, it's often something that's seen as trivial or mundane, and that's often because it's through this lens of acute, transient, episodic, episod, and most of the time it is right. 75% Of people with Vaginas will have thrush at some point in their life.It's usually self managed over the counter with pharmacy care and symptoms resolved within a few days.But where recurrent thrush differs is when those symptoms keep coming back so that itching, burning pain and irritation becomes sometimes cyclical, sometimes repetitive. And I spoke to three or two patients who all had different durations of heat know, happening every two weeks, every month.And what they often found was because they were accessing fragmented care.So, you know, going to the pharmacy, sometimes going to the gp, sometimes maybe seeing sexual health, it was often seen as again, that mundane, one off, trivial case. And it was really hard to trace those patterns across care, especially due to a lack of continuity. Right.If you're trying to track a pattern but nobody is following you up, it's really difficult to, to capture those. So I think it's a few layers of one.I explore how these sort of social dimensions keep it seen as something maybe less long term, but then also in the ways that sort of care was fragmented made it harder for those patterns to be picked up and then to transition the care moving away from, you know, acute one off prescriptions of an antifungal medication to something that required repeat, repetitive, enduring, you know, testing, treatment, retesting of treatments.Speaker A00:03:56.060 - 00:04:09.970Absolutely. And I think what's interesting is that your papers describe recurrent thrush as something that's accumulative and cyclical over time.And you mentioned that it's not just these sort of one off episodes. Can you explain what patients meant by that?Speaker B00:04:10.210 - 00:05:13.850Yeah.So often, I think when we talk about healthcare, journeys are presented in a way that's quite linear and straightforward that, you know, you see a healthcare professional, you get treatment, you go home, you start to feel better. But with recurrence, something interesting happens where people aren't, you know, returning to the start.It's not that you go back to a blank page and then restart your healthcare journey every time you're carrying with you everything, everything that's amassed through healthcare encounters, what you've seen online, what you discuss with friends, and that is all carrying through to those consultations.And I think what was really important there was acknowledging that for many people there was a lot to unpack there and often they felt that it wasn't being acknowledged in those clinical spaces. It was seen as, oh, it's just thrush. And that's why in one of the papers the title is, it's not just thrush, it's recurrent thrush.And that's a quote from One of the participants who was speaking about the importance of labeling and distinguishing this condition, especially in terms of the impacts it had on people's lives and also the approaches and pathways that would be needed to properly treat it.Speaker A00:05:14.330 - 00:05:32.570And this is an issue that we see across clinical care and women's healthcare. But a lot of participants described feeling dismissed or not listened to.And I wanted to just get your perspective from your wider sort of work in this area is how much of that reflected wider issues in women's health care, do you think?Speaker B00:05:33.170 - 00:06:46.980Yeah, I mean, we know there's increasing conversations, right, with the women's health strategy, with the Cumberlage report, about how people's pain is often dismissed based on their gender. And that definitely came across in the studies. But I think what was interesting was that both patients and clinicians were aware of this.And something that is quite interesting was in the diagnostic paper, we look at sort of those moments where there were sort of miscommunication or differing expectations between patients and clinicians, clinicians, where clinicians were, you know, operating on a standard guideline that requires two swabs, two positive swabs for a thrush within a year to diagnose recurrent thrush.But when that wasn't communicated to the patient, of being told we need to accumulate these number of swabs, what the patients thought was happening was, oh, they're swabbing me again, they're not listening to me, they don't believe me.So it was interesting where the dismissal was often in those moments of, you know, it wasn't healthcare professionals saying, this isn't important, or please don't come see me about this. It was really in those sort of small details where patients were operating on one framework and clinicians on another.And there were these gaps in communication. And that's why our papers seek to address some of those gaps with some recommendations as well.Speaker A00:06:47.620 - 00:07:04.640Yeah, and as you mentioned, one of the papers is called it's not just thrush, it's recurrent thrush.And I wonder what you felt were the key challenges around actually recognizing recurrence in primary care, as opposed to it just being a, a one off episode.Speaker B00:07:04.720 - 00:09:30.220There's multiple layers to this, I think, in terms of the. The papers are sort of split in terms of the diagnostic journey and then the healthcare journey.But that's sort of an artificial split in some ways, because what we saw a lot was, you know, patients trying to seek out continuity of care to get someone to notice the pattern that they were starting to see and assign a label to it and we saw some hesitancy with this in clinicians who said, you know, I'm not going to use the term recurrence because that sounds like it's something serious or sounds like it's chronic. And they saw that being helpful.But then for patients they found that really challenging because they said, you know, they just see it as thrush, they just see it as a one off case, they're not recognizing it when often...

In this episode of Accelerated Health with Sara Banta, I'm joined by Dr. Fenwa Milhouse and Heather Florio to talk about why so many women are repeatedly diagnosed with UTIs when the root cause may be something entirely different.Millions of women suffer from chronic urinary symptoms like burning, urgency, frequency, pelvic pain, and discomfort — only to be prescribed endless rounds of antibiotics that never fully solve the problem. Dr. Milhouse and Heather explain why many of these cases are often misdiagnosed and how underlying issues such as pelvic floor dysfunction, hormonal imbalances, inflammation, vaginal health changes, and other hidden factors may actually be driving the symptoms.We also discuss the dangers of overusing antibiotics, why traditional testing can miss the full picture, and what women need to know to finally get answers and proper support.If you've been struggling with chronic urinary symptoms, recurring infections, pelvic discomfort, or unresolved women's health issues, this episode is a must-listen.Follow our guests:• Dr. Fenwa Milhouse Instagram: https://www.instagram.com/drmilhouse • Heather Florio Instagram: https://www.instagram.com/hmflorio Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Methylene Blue® https://www.acceleratedhealthproducts.com/products/accelerated-methylene-blue-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

Recurrent miscarriage is one of the hardest and most sensitive topics in women's health, and in this episode, Lauren Allen opens up a practical, research-informed conversation about why miscarriages happen, when to look deeper, and what testing may help reduce future risk.Listen in to hear Lauren share:What miscarriage is, how common it isThe difference between a random miscarriage and recurrent pregnancy lossRoot cause of miscarriage, including thyroid dysfunction, PCOS, nutrient deficiencies, gut health, clotting disorders, lifestyle factors, and inflammationWhat tests to do after repeated losses+So much moreConnect with Lauren:Get my FREE PCOS Guide hereJoin the Empowered Path to Pregnancy hereInstagramWork With MeThank you so much for listening to the About Health and Hormones Podcast! If you loved today's episode, I would love to know! Please leave a rating and review so I can make this podcast even better for you all. I would love to connect with you.I'm so glad you were here today, and I wish you all health and happiness!This episode was edited and produced by Intent Media.This podcast uses the following third-party services for analysis: Podcorn - https://podcorn.com/privacy

Building Community and Support with MilSpouse Fest Director Jessica Manfre Host Ashley welcomes Jessica Manfre to the “Ruck Up Buttercup” podcast to discuss supporting military spouses through connection, resources, and events like MilSpouse Fest. Jessica shares her background marked by early loss, meeting her Coast Guard husband young, experiencing isolation without a spouse network, and pursuing education and service, becoming a licensed clinical social worker who still sees military patients. She explains her path into military writing and then joining Recurrent's military brands, ultimately becoming director of MilSpouse Fest in 2025. They describe MilSpouse Fest as a free, family-friendly event with a resource marketplace and community-building that reduces barriers like childcare and loneliness. Upcoming fests include Norfolk and San Diego, plus an international tour to Osan and Camp Humphreys in South Korea and Puerto Rico, with attention to bilingual support. Jessica's advice: embrace new experiences and help pave the way for spouses coming behind you. 00:00 Welcome and Introductions 01:50 Jessica's Early Life 02:55 Coast Guard Spouse Reality 04:01 Finding Purpose in Service 04:33 Spouse Career Challenges 05:54 Ashley's Military Brat Story 09:40 Why Community Matters 14:22 Joining MilSpouse Fest 17:13 First Fest Experience 21:55 Overseas Tour and Sponsors 23:38 Kids Welcome at Events 24:43 Raising Volunteer Kids 25:03 Military Community Then Now 25:18 Early Lessons in Service 25:57 Fisher House Memories 26:45 New Spouses Need Support 28:05 Collaboration Not Competition 29:05 No One Path Fits All 30:36 Fests and Guard Support 33:35 Take the Leap Solo 36:04 Use Resources and Show Up 40:48 Loneliness and Connection 41:24 Curating Help In Person 43:51 Deployed Love Origins 44:22 Volunteer to Find Purpose 48:08 Passing the Torch Forward 49:30 Advice Embrace the Yes 52:07 Closing Invite and Support Find us or reach out here: Website: www.deployedlove.org/podcast Facebook: www.facebook.com/ruckupbuttercup Instagram: www.instagram.com/ruckupbuttercuppodcast Email: ashleybrown@deployedlove.org More information on MilSpouseFest Website: https://milspousefest.com

Dr. Centor discusses interventions to prevent kidney stones with Dr. Gary Asher.

Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study by Taylor & Francis Group

Dr. Aimee Baron is a pediatrician and the founder of I Was Supposed to Have a Baby, a nonprofit supporting people through infertility, miscarriage, pregnancy loss, and related struggles in the Jewish community. After walking through secondary infertility, miscarriage, multiple unexplained losses, and eventually a surprise twin pregnancy, Dr. Baron turned her personal pain into a mission to help others feel less alone. Through shared stories, support groups, education, and her podcast, she works to reduce isolation and create more sensitive communal spaces.Listen in to hear Dr. Baron share:Her personal fertility journey, including secondary infertility, miscarriage, and repeated pregnancy lossWhy she founded I Was Supposed to Have a Baby and how storytelling helps break the silence around infertilityPractical ways communities can be more sensitive, from changing the way we ask about family to being mindful at Shabbos tables and simchasHow to support a friend who is struggling while sharing your own pregnancy news with careHoliday survival strategies for people facing infertility or loss, including setting boundaries, opting out when needed, and creating private spaceWhy all forms of infertility-related grief deserve validation, including circumstantial infertility for singles+So much moreConnect with Lauren:Get my FREE PCOS Guide hereJoin the Empowered Path to Pregnancy hereInstagramWork With MeThank you so much for listening to the About Health and Hormones Podcast! If you loved today's episode, I would love to know! Please leave a rating and review so I can make this podcast even better for you all. I would love to connect with you.I'm so glad you were here today, and I wish you all health and happiness!This episode was edited and produced by Intent Media.This podcast uses the following third-party services for analysis: Podcorn - https://podcorn.com/privacy

In this week's episode, Taylor shares her journey from a breech caesarean to a VBAC that, on paper, had almost everything people fear: induction, fetal distress, instrumental birth, retained placenta, postpartum haemorrhage...And yet, her story is not one of fear or trauma.Taylor speaks about what it felt like to be informed, make decisions in real time, and hold her ground when it mattered. But also when to shift when it felt necessary.There's a thread running through this conversation that so many women need to hear:It wasn't the absence of intervention that made this birth feel positive. It was the presence of choice.We also talk about:– navigating pregnancy after loss and the weight that brings– the deep dive so many women go on when planning a VBAC– advocating for yourself in a system that doesn't always expect it– how “risk” isn't one-size-fits-all– and why knowing your options changes everythingThis is one of those brilliant stories that challenges the idea that a “good birth” has to look a certain way.Because sometimes, everything can go “wrong”, and still be empowering. When women's choices are respected and decisions are made by them and not for them, it can still be incredible.Taylor shares:"I have experienced two very different births that I look at positively, despite some complications. I planned for my VBAC for many years and although I was equipped with as much knowledge as possible, my baby had other ideas. A great reminder that we can only control so much when it comes to birth. I love all things pregnancy and birth and enjoy sharing birth stories with other women. I hope to empower other women with my story so that ‘intervention' doesn't always needs to be looked upon as negative or related to trauma. The power of informed consent cannot be understated. "

Listen to Andrew Duckworth, Colin Forde and David Keene discuss the paper 'Supervised versus self-managed rehabilitation for patients with an acute first-time or recurrent patellar dislocation: the Physiotherapy Rehabilitation Post Patellar Dislocation (PRePPeD) external pilot randomized controlled trial and embedded qualitative study' published in the March 2026 issue of The Bone & Joint Journal.Click here to read the paper.If you'd like to get involved with the main trial if it is funded, please contact prepped@ndorms.ox.ac.uk.To find out more about the 2026 Annual Scientific Meeting of ISHA, visit www.ishasoc.net.Find out as soon as the next episode is live by following us on X (Twitter), Instagram, LinkedIn, Tik Tok or Facebook!

In this episode, Megan shares her journey through recurrent pregnancy loss, chronic illness, medical trauma, and a life-threatening birth experience that led to her son's premature arrival. Her story sheds light on the complexities of pregnancy after loss, the realities of navigating the healthcare system with chronic conditions, and the lasting impact of birth trauma and a NICU stay.

This episode covers recurrent infections in children.Notes: https://zerotofinals.com/paediatrics/immunology/recurrentinfections/Questions: https://members.zerotofinals.com/Books: https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

Shoot us a Text.Episode #1327: Dealers lose service share to quick lubes, EVs prove stronger range retention, and Chinese vehicles gain global credibility at the Beijing Auto Show.Dealership service lanes are losing ground as quick lube shops quietly gain share in 2025. New data shows fewer transactions and shrinking revenue for dealers, with pricing strategy emerging as the key battleground in keeping service customers loyal.The study analyzes credit and debit transactions across all service channels including dealerships, independents, quick lubes, and tire chains.Overall service transaction dollars fell 8.3 percent, but dealers declined faster at 11 percent.Dealership service transactions dropped 13 percent year over year, the steepest decline among all segments tracked.Quick lube shops gained market share while raising prices more slowly than dealerships, attracting cost-conscious customers.Even with free OEM-paid maintenance, dealers are struggling to retain customers in the critical first two years of ownership.“The quick lubes are what everybody should be worried about,” said Ducker Carlisle's Nate Chenenko.Electric vehicle range isn't fading the way many buyers fear. New data from over a billion miles of driving shows modern EVs are holding onto their range far better than expected, thanks to both improving battery tech and smarter software.Recurrent data shows EVs retain about 97% of range after three years and 95% after five years of ownership.The study is based on real-world driving data, factoring in climate, usage, and battery age, not just EPA estimates.About 68% of 2023 model-year EVs are still exceeding their original EPA range today.Automakers are offsetting degradation with OTA updates and built-in battery buffers that unlock over time.At the Beijing Auto Show, American YouTuber Ethan Robertson of Wheelsboy is giving global audiences a firsthand look at Chinese EVs, helping shift perception from “cheap copycats” to serious innovation leaders.Robertson led international visitors through the Beijing Auto Show, showcasing China's latest EVs and tech-forward designs.Perception has shifted dramatically, with Chinese brands now recognized for advances in batteries, software, and charging.Attendees highlighted futuristic interiors and features, calling the vehicles a “new generation” of driving experience.Competitive pricing remains a major disruptor, with fully loaded EVs around $30,000 undercutting U.S. options.“Our comment section is full of people saying, ‘I can't believe the government won't allow them to sell this car in my country,'” said Robertson.Join Paul J Daly and Kyle Mountsier every morning for the Automotive State of the Union podcast  as they connect the dots across car dealerships, retail trends, emerging tech like AI, and cultural shifts—bringing clarity, speed, and people-first insight to automotive leaders navigating a rapidly changing industry.Get the Daily Push Back email at https://www.asotu.com/JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/

Host Jake New summarizes and offers insights into the JCO article by Licitra et al., "Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study." LINK TO FULL TRANSCRIPT

Dr Tanyel Zubarioglu discusses the case of a young woman with years of severe abdominal pain, neurological symptoms, anxiety, and repeated hospital visits, initially thought to represent familial Mediterranean fever. In this episode, we explore how a simple urine test during an acute attack changed everything, and why some metabolic diagnoses remain hidden in plain sight. Read the paper here: https://link.springer.com/article/10.1186/s13023-026-04308-3

Send us Fan MailDo you ever feel a bit lost when you see someone with a sore mouth, a furry tongue, or bad breath? This episode is your rapid confidence boost, delivered as a cheeky (virtual) 'million pound question' quiz between Nik and Fi. You'll get a practical, primary care friendly approach to:Dry mouth ( what it is, common causes, and when to worry)Oral thrush (the assessment bits we all forget),Recurrent mouth ulcers (types, triggers, red flags for urgent referral, and what actually helps)Halitosis (from hygiene to halitophobia… plus one surprising cause). Press play now and prepare for faster, safer, calmer oral consultations afterwards.Send us your feedback podcast@redwhale.co.uk or send a voice message Sign up to receive Pearls here. Pearls are available for 3 months from publish date. After this, you can get access them plus 100s more articles when you buy a one-day online course from Red Whale OR sign up to Red Whale Unlimited.  Find out more here. Follow us:  Facebook, Instagram, LinkedInDisclaimer: We make every effort to ensure the information in this podcast is accurate and correct at the date of publication, but it is of necessity of a brief and general nature, and this should not replace your own good clinical judgement, or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular, check drug doses, side-effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in this podcast.

Dr. Patrick Micaroni is a pediatric dentist and practice owner from New York. We talk about just about every topic related to pediatric dentistry that you can think of, including:- How he bought an existing practice and kept the selling doc on as an associate- Why residency was truly "the good ol days"- Recurrent decay on teenagers- Why class IIs are terrible- Cloud-based dental software, pros and cons- Challenges of employing expensive hygienists in states where assistants can't coronal polishThis is a great casual episode where we vent about the common pitfalls that drive us crazy as pediatric dentists.

Shahad Abdulsahib discusses a phase 1 clinical trial of intracerebroventricular bivalent EGFR and IL13Rα2 CAR T cells for recurrent glioblastoma, published in Nature Medicine.

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Gastroesophageal cancer (0:00) Recurrent colorectal cancer (5:43) Colorectal cancer with brain metastases (9:59) CME information and select publications

Fifty to sixty percent of women will get a urinary tract infection at least once in their lifetime — and for many, it won't stop there. So why does almost every conversation about UTIs still end with the same answer: another antibiotic? In this episode of the Your Health University Podcast, host Jamie Preston sits down with Madison Browning, Executive Director of Clinical Services in the Specialty Department at Your Health, to explore what's actually possible when we stop reacting and start preventing. Madison oversees the urology and nephrology divisions and brings the kind of front-line clinical perspective that turns confusing medical information into something anyone can act on. Together, they cover: Why repeated antibiotic use can actually make you more prone to future infections — and what antibiotic resistance really means for your body The honest truth about cranberry: there is science behind it, but probably not in the form you've been using What D-Mannose is, how it works, and why it practically fills the hooks bacteria use to grab onto your urinary tract Vaginal estrogen — the most evidence-backed, most underused prevention option for postmenopausal women, and why the word "estrogen" shouldn't automatically trigger fear The lifestyle changes that cost nothing, require no prescription, and form the foundation of any prevention plan This isn't about abandoning medical care. It's about having a better conversation with your provider — one that goes beyond treating the infection in the moment and starts asking why it keeps happening at all. www.YourHealth.Org

The week marks one month since the United States and Israel attacked Iran. We take a look at the impact the resulting war has had on the women and children of the country. Krupa Padhy is joined by BBC Chief International Correspondent Lyse Doucet and Ghoncheh Habibiazad, Senior Reporter from BBC News Persian.Recurrent miscarriage is when you experience more than two or three pregnancy losses, and it affects around one in 100 women. A device designed to offer more care and dignity during miscarriage, and that could aid greater understanding, is now being used in 28 hospitals across the UK. Engineer Laura Corcoran created a miscarriage collection cradle after she suffered the loss of her third pregnancy. She is calling for a wider roll-out of the device. Laura speaks to Krupha, along with Siobhan Quenby, Professor of Obstetrics at the University of Warwick.A new exhibition at Kensington Palace is celebrating the 150th birthday of Princess Sophia Duleep Singh – the Punjabi princess and suffragette. The Last Princesses of Punjab exhibition explores her life and five other women who shaped her. Krupha talks to the curator Polly Putnam and journalist and Radio 4 presenter Anita Anand, author of Sophia: Princess, Suffragette, Revolutionary.Another chance to hear our interview with Janet Willoner, known as the tree growing granny. Janet has grown more than 4,000 trees in her garden.  She forages for seeds, grows them, and they eventually grow in forests in her local area of North Yorkshire.  Zoom bombing involves crashing into a meeting and taking it over - more often than not showing shocking content including pornography. Businesswoman Lou Robey was holding a meeting on International Women's Day when it was zoom bombed. Lou has put out a call for action for media platforms and the wider community to act. She and Gina Neff, Professor of Responsible AI at Queen Mary, University of London join Krupha to discuss.

In this episode, Nicol shares her story of baby loss, opening up about her experiences of recurrent miscarriage and stillbirth, and the impact it's had on her life.She speaks honestly about the weight of grief and how isolating loss can feel, especially when the world around you keeps moving. Nicol reflects on how finding support through social media and connecting with others who truly understand helped her feel less alone, and gave her a sense of purpose in the midst of everything she was carrying.We talk about the importance of having spaces where grief is welcomed, not silenced, and how sharing your story, even when it feels hard, can be part of healing. Nicol also shares how therapy and self-compassion helped her begin to rebuild her confidence, and how she navigates conversations about loss with her children and the people around her.This episode is about connection, honesty, and the quiet strength that comes from being seen. A reminder that even after the most painful experiences, there can still be moments of hope.

In this episode, Prof Chapman breaks down recurrent miscarriage, including which baseline tests are truly worth doing, which findings actually change treatment, and which commonly suggested tests have weak evidence behind them. He explains the role of embryo chromosomal abnormalities, balanced translocation, uterine assessment, antiphospholipid syndrome, sperm DNA fragmentation, and when options like progesterone or IVF with genetic testing may be worth considering. Explore the 'Prof. Michael Chapman - The IVF Journey' Facebook Page, your reliable destination for cutting-edge insights and guidance within the realm of In Vitro Fertilization (IVF). Don't miss out on the IVF Journey podcast; stay informed with the latest episode updates. Tune in for expert discussions and valuable information on navigating the intricate path of IVF.

Interview with Trisha M. Wise-Draper, MD, PhD author of Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial. Hosted by Paul C. Bryson, MD MBA. Related Content: Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma

Interview with Trisha M. Wise-Draper, MD, PhD author of Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial. Hosted by Paul C. Bryson, MD MBA. Related Content: Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma

Dr. Erik Goodwyn is a practising psychiatrist with a background in neurobiology who bridges the worlds of neuroscience, Jungian psychology, and fantasy. Erik is co-editor-in-chief of the International Journal of Jungian Studies and has written dozens of academic papers along with books on the neurobiology of the gods, dreams, and archetypes. Last year he published his first fantasy novel, King of the Forgotten Darkness, which won the Literary Titan Golden Book Award.________________In this return visit, we dive deep into who actually creates the dream – the Invisible Storyteller that isn't your conscious self. We explore the neuroscience behind this, discussing the Default Mode Network, Salience Network, and Executive Control Network, and what they reveal about dreaming, meaning-making, and the deeply non-egoic nature of consciousness. Erik shares clinical insights into Dissociative Identity Disorder as evidence of an underlying organising principle, we tangle with what it means for consciousness to be "non-egoic," and we work through his groundbreaking definition of archetypes through Cognitive Metaphor Theory. It's a conversation that challenges everything you think you know about who you are.________________

Priyanka Jain, co-founder and CEO of Evvy, shares how being dismissed by the medical system led her to help transform women's health through better vaginal microbiome data. We talk about why the vaginal microbiome matters, how dysbiosis can drive inflammation even without obvious symptoms, and why women still face outdated standards of care. We also cover recurrent UTIs, yeast infections, fertility, pregnancy, postpartum, perimenopause, probiotics, and at-home testing. This is a practical conversation for women who want to better understand their bodies, stop brushing off symptoms, and use better data to support long-term health. Join my NEW private community at thelongherlife.com for ongoing protocols, live coaching, and deeper support. WE TALK ABOUT:  12:00 - Why the vaginal microbiome is one of the most overlooked biomarkers in women's health 14:40 - Why vaginal discomfort is one of the top reasons women seek care 18:30 - Why pH shifts can allow harmful bacteria to take over 20:50 - How women normalize symptoms and miss signs of imbalance 22:45 - Why baseline testing can help women get more attuned to their bodies 26:55 - How the vaginal microbiome changes during pregnancy and postpartum 30:15 - What recurrent yeast infections and UTIs may really be telling you 34:50 - What cotton underwear, synthetic fabrics, and moisture may mean for infections 35:45 - The unanswered questions around period products and vaginal health 36:50 - What research is starting to show about IUDs and the vaginal microbiome 39:05 - How vaginal microbiome testing could one day help track menopause progression 41:00 - How community-driven research is changing the future of women's health RESOURCES: Join my NEW private community at thelongherlife.com for ongoing protocols, live coaching, and deeper support. Download the non-toxic baby registry guide to reduce toxic exposure and make confident, evidence-informed choices for your family—free. Evvy's website and Instagram LET'S CONNECT: Instagram, TikTok, Facebook Shop my favorite health products Listen on Spotify, Apple Podcasts, YouTube Music

Guest Dr. John Gore and host Dr. Davide Soldato discuss JCO article, "12-Month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent Non-Muscle Invasive Bladder Cancer," which compares radical cystectomy and bladder sparing therapy for patients with recurrent high-grade non-muscle invasive bladder cancer. Dr. Gore and Dr. Soldato focus on the study's patient-centered approach, eligibility criteria, and quality of life after treatment. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author Dr. John Gore, urologist at Fred Hutch Cancer Center and professor of urology at University of Washington School of Medicine. Today, we will be discussing the article titled, "Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer." Thank you for speaking with us, Dr. Gore. Dr. John Gore: Thank you so much for having me. Dr. Davide Soldato: So, I just want to jump right in. We know that patients who are diagnosed with recurrent high-grade non-muscle-invasive bladder cancer can be treated with two different approaches. So, one is radical cystectomy, and the other is bladder-sparing therapy. I just wanted to understand: what was the gap that you were trying to fill with this study? In particular, one point that is very important is that this study is very centered on the preference of the patients. Why did you choose this endpoint instead of going for more solid oncology-based endpoints? Dr. John Gore: Yeah, so CISTO was a study that was derived really organically from patient engagement. I think as a clinical gap in care, making a decision about when to pursue radical cystectomy for patients with non-muscle-invasive bladder cancer is a tough decision for us as clinicians. We did some engagement work partnered with the Bladder Cancer Advocacy Network and my partner Angela Smith, and found that it is also a huge gap for patients. You know, they are very anxious about recurrences, and the decision about when to take out the bladder is a very difficult one. We did an evidence synthesis and found that evidence guiding this decision is fairly limited. The reason we chose more of a patient-reported endpoint is several-fold. One is that we, as part of our engagement work, also worked with our patient survey network to identify outcomes that were important to patients. Some of those are the same outcomes that we care about as clinicians - recurrence-free survival and metastasis-free survival - but several outcomes came out that were more patient-centered. These were patient-reported outcomes such as the burden on my finances, the burden on my caregiver or loved one, and the ability to return to physical activities that are important to them. Part of what is unique about CISTO is that this was a contract with PCORI where we knew we would only have about 12-month outcomes for the majority of our patients. That is too early to really derive a lot of the clinical outcomes, but we are able to answer that patient-centered question of, "Am I going to be able to return to physical activities that are important to me?" And that was the genesis of that as the primary endpoint. Dr. Davide Soldato: So, who were the patients that were eligible to participate in the CISTO trial? What were the key eligibility criteria? This is very particular to this study because this was actually an observational study. Why did you think that such a pragmatic approach still can inform us on what is the best treatment approach for these patients? Dr. John Gore: The intent of CISTO was not necessarily to focus on the tightly defined BCG-unresponsive patient population. That is a clearly important patient population, but every day we are all faced in our real-world practice with patients with challenging, high-grade recurrences that don't fit neatly into that BCG-unresponsive box. The reason we chose a broader inclusion was to help doctors and patients answer these same questions they have when it doesn't fit nicely into this BCG-unresponsive category. You know, maybe their BCG exposure was two years ago, but now they are having a recurrence after intravesical chemotherapy. That is no less challenging a clinical conundrum, and we wanted to be able to enroll those patients. Other key inclusions were that all of the patients in CISTO had to have BCG at some point, and they had to have recent exposure to some adjuvant instillational or intravenous therapy like pembrolizumab. We also had some exclusions that were important. They couldn't be participating in a phase 2 clinical trial, and they couldn't have had a prior upper tract urothelial cancer. The other point about the observational trial design is I think a really important one. Part of our engagement work also asked patients about their willingness to randomize. There is a ton of literature in our history of trials that failed to accrue well when they were comparing a large-scale surgical intervention with a more conservative management strategy. What we found is only about 10% of patients would be willing to randomize when the clinical comparison is between radical cystectomy and bladder-sparing therapy. So it was very clear that an observational study design was the only way we were going to get evidence to inform clinical care when one of the key comparators was radical cystectomy. And so that is why we utilized the observational trial design. Dr. Davide Soldato: Starting to go deeper into the results, you mentioned before that the endpoint you chose for this trial was really centered on what patients thought was more important to them. In particular, the primary endpoint of the study was physical function as measured by the EORTC QLQ-C30 questionnaire. I just wanted to understand: first, did you have a solid hypothesis regarding how physical function could be impacted by either radical cystectomy or bladder-sparing treatments? And second, what were the key results of the study? Dr. John Gore: We figured that at 12 months after enrollment, given the burden and morbidity of a radical cystectomy, that patients in the radical cystectomy arm would have worse self-reported physical functioning than patients in the bladder-sparing therapy arm. We did hypothesize that some of our secondary outcomes might potentially be better after radical cystectomy, such as recurrence-free survival and potentially some other cancer-specific outcomes, because it is a more definitive management strategy. For our primary endpoint, however, we hypothesized that it would be worse. What we found, and the key finding of our study, is that at 12 months after enrollment, physical functioning was not different between patients undergoing radical cystectomy and patients undergoing bladder-sparing therapy, which is just important in terms of clinical counseling because it just means that you can tell your patients, "Gosh, if we could fast-forward your life six to nine months after this procedure, your physical functioning would be similar to as if you had been able to keep your bladder." Dr. Davide Soldato: And you mentioned that there were some key secondary endpoints of the study, which included both other dimensions of quality of life and also hard clinical outcomes. We mentioned metastasis-free survival, for example. Going a little bit into the key secondary quality of life outcomes, we know that radical cystectomy can impact physical functioning, but we also know that bowel, sexual symptoms, and also genitourinary symptoms might potentially be impacted by this type of treatment. We also know that, especially in a system like the US, financial toxicity can be a significant burden for patients. Considering the two different approaches, was radical cystectomy better also in other key secondary quality of life outcomes, and was financial toxicity different between the two arms? Dr. John Gore: Thank you for highlighting some of the really important secondary outcomes that I think are really important to trying to figure out what's best for your patients. Some of the main ones were some of the bladder cancer-specific quality of life outcomes you highlight. Urinary quality of life was worse at enrollment in patients in the radical cystectomy arm but was no different 12 months after. What is unique about how we measure that is we used an instrument called the Bladder Cancer Index because we're comparing a population of patients who have lost their bladder with a population of patients who have retained their bladder, and there are different considerations by gender. And so that instrument is agnostic to urinary diversion status and gender. We found that bowel function and sexual function were worse in the radical cystectomy arm. It appeared that bowel functioning was getting better to the point of near equivalence at 12 months in the radical cystectomy arm but was still inferior to bladder-sparing therapy, and that probably relates to the fact that we use the bowel as part of the urinary diversion, and that causes some transient disruption in bowel function. Financial toxicity is an outcome we weren't initially planning on having as part of the CISTO study, but based on that patient feedback, we made that one of our key secondary outcomes. That actually demonstrated superiority in the radical cystectomy arm. I think it's important that we remember that when we do bladder-sparing therapy, those patients are predisposed to a number of visits to our office, whether they're for instillational therapies or cystoscopy surveillance visits. Sometimes that involves the patient themselves, and sometimes that involves a caregiver. We live in an area with a very large geographic catchment, so sometimes that involves overnight hotel stays and airfare. It can be a particular burden, as you made mention, especially in our healthcare system. Dr. Davide Soldato: Going back to the quality of life dimensions and especially considering the different treatments, 50% of the patients received radical cystectomy with robotic surgery. Did you look a little bit into whether the type of surgery that they received might potentially impact on these dimensions of quality of life? Dr. John Gore: These are some questions that a lot of urologists have asked us in the surgical arm, related to surgical approach, so robotic versus open, and urinary diversion type. We sometimes reconstruct the urinary tract with an incontinent diversion called an ileal conduit where the urine drains tonically into a bag, and we sometimes do a continent diversion where someone typically will have a neobladder, where you reconstruct a sphere reservoir out of intestines and sew it to the urethra. About 20% of patients in the radical cystectomy arm in CISTO had a neobladder. We have not yet looked at specific surgical factors and some of those outcomes. That is one of the secondary analyses that we have planned, but we have not drilled into how different surgical approach factors can affect some of our outcomes. Fortunately, we have about 200 patients in the radical cystectomy arm, so it's enough patients that hopefully we can look at some of those factors in the future. Dr. Davide Soldato: Going back to the clinical endpoints, you mentioned that several of these were measured. There was metastasis-free survival, cancer-specific survival, and progression-free survival. We now have the data at 12 months. I am just wondering if you can comment on those when comparing the radical cystectomy with the bladder-sparing techniques. Dr. John Gore: I think importantly, bladder cancer-specific survival was very high in both arms, over 95% at one year. So both patient populations do very well in terms of cancer-specific and overall survival at one year. You know, when you take out the bladder, you're taking out a big source of recurrences. Not surprisingly, there was a marked reduction in recurrences in the radical cystectomy arm, so they had better recurrence-free survival. There actually was worse progression-free survival in the radical cystectomy arm, but there is a big asterisk to that. As you noted, it is an observational study, and one of the areas of imbalance in the study is that we had higher cancer severity in the radical cystectomy arm. So there was about a 20% rate of progression at the time of radical cystectomy to muscle-invasive and node-positive disease. Of those progressions, the overwhelming majority of them were progressions at the time of radical cystectomy, which I think speaks to a couple of important factors. Number one is the challenge in staging these patients. Our staging of non-muscle-invasive bladder cancer is very reliant on our resection. And so there is this risk of understaging our patients. Number two is just the challenge of decision making, that we fear losing our window of cure in this patient population, which is why we try to steer some patients toward radical cystectomy, and that progression figure kind of speaks to that. Dr. Davide Soldato: Also, one of the factors that was most common in the patients who received radical cystectomy was the presence of other high-risk features. For example, non-urothelial histology, which I think is something that in clinical practice we tend to fear a little bit in terms of recurrence, and so it might potentially bias a little bit towards proposing more strongly radical cystectomy to the patient. Another thing that I wanted to have a comment on, so this is not really in the paper, but I think it speaks a little bit to how the data will evolve over time. Do you imagine these clinical outcomes changing over time, and do you think that with higher maturity of these endpoints, this study might be even more informative when counseling patients regarding what they are obtaining with a radical cystectomy versus the other type of treatments? Dr. John Gore: You know, I think in this cancer universe, 12-month outcomes are great, but I think we all want to see two-year and five-year outcomes. We're very fortunate to supplement the work that we've done in the initial CISTO study, we're very fortunate that we've gotten supplementary funding from the National Cancer Institute to get long-term outcomes in this patient population. So we are continuing to follow all of our CISTO study patients to get two-year and five-year outcomes. What we expect to find is the accrual of new events in the bladder-sparing therapy arm. About 7% of patients in the bladder-sparing therapy arm underwent cystectomy in the first year, but that number will probably go up either as they have recurrences or progression events. We definitely expect the recurrence-free survival to continue to have superiority in the cystectomy arm, but we probably will see the progression events equilibrate as more progression events accrue in the bladder-sparing therapy arm. Maybe by five years, we hypothesize that we'll see clinical superiority in the radical cystectomy arm. By then, we might also see mortality events that separate bladder cancer-specific survival and overall survival between the two arms potentially. But we don't know. Hypothetically, cystectomy has its own downstream risks. It is a major reconstruction with some metabolic sequelae and renal functional sequelae, and so there may be some general medical events that accrue in the cystectomy arm that are also impactful. Dr. Davide Soldato: One other thing that I think should be complimented on this study is that you also looked at several other endpoints that might be important for patients. For example, anxiety symptoms and depression symptoms. Dr. John Gore: Yeah, I think one of the other key secondary outcomes we looked at were mental health outcomes. We utilized the PROMIS domains of anxiety and depression. Not unexpectedly, our radical cystectomy arm patients exhibited higher anxiety symptoms and higher depression symptoms at enrollment. What we found is at 12 months, they actually had significantly lower anxiety and depression than patients in the bladder-sparing therapy arm. We hypothesized in this paper that that actually relates probably mostly to cancer-specific anxiety. You know, when you experience this cavalcade of recurrences, it just breeds an anxiety about adverse cancer-specific outcomes, and by taking out the bladder, you kind of eliminate this prevalent source of anxiety. We followed up the study with a qualitative piece where we interviewed 50 patients and 20 caregivers. Based on those interviews, and that's just a sample of the patient population, it did seem to be cancer-specific anxiety that was driving a lot of those responses. Dr. Davide Soldato: I would like to end with a methodological consideration on your part because we said that this was an observational study. Frequently we tend to think that observational studies come with a lot of bias, and so we tend to downgrade a little bit the results. But I think that a lot of the merit that goes in the CISTO study that was published in the JCO, and I think it also speaks to the fact that this is very high-quality data, comes with the fact that the methodology behind this study was really robust in terms of informing us. Even with this observational study that, as you said, was the only one that we could perform considering the patient population. So just a comment on your part also to speak to the solidity of the data that was published. Dr. John Gore: Importantly, you know, if you look at ClinicalTrials.gov or other sources, CISTO is the only trial that has radical cystectomy as a major comparator. In many ways, this study is our only source of evidence for radical cystectomy. So we'd rather have flawed observational evidence than no evidence at all. We all experience flaws of our RCTs as well. They tend to be these narrowly defined patient populations that may not match the patient in front of you. So I think there are unrecognized flaws on the other side as well. The way that we try to counterbalance that, and none of these techniques are perfect, but we used a strategy called 'targeted maximum likelihood estimation'. Like many methods, such as propensity scores or instrumental variable analysis, what we're trying to do theoretically is coax randomization from non-randomized data. And TMLE, which is the technique we use, tends to be pretty robust to that. So it's the best available way that we can try to counterbalance the bias based on age and clinical severity between the two patient arms. I also think what's important about this is that even when there are biases, I think we are able to infer those out and still extract meaningful details from the data. So even with the biased data, I think we all glean some really important clinical learnings from it. Dr. Davide Soldato: Absolutely, but I would also say that in terms of observational data, the work that you have done is really something that makes us quite confident about what you found in the CISTO study. So with this, I would like to thank you again for joining us today. Dr. John Gore: Thank you so much, and thank you for highlighting the CISTO study. We are very excited about the data. Dr. Davide Soldato: So Dr. Gore, we appreciate you sharing more on your JCO article titled, "Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Guest Disclosure Dr. Gore:Consulting or Advisory Role: Astellas Pharma  

This episode is an invitation to slow down, find meaning in the quiet moments, and celebrate the fullness of our identities. To learn more about Immigrantly, visit our website http://immigrantlypod.com and follow the host Saadia Khan @itssaadiak You can also subscribe to the Immigrantly Channel on Apple at https://podcasts.apple.com/us/channel/immigrantly/id6473736795?hasPaidContent=true

Podcast Host and Interviewee: Shahad Abdulsahib, PhD Candidate, UT Health San Antonio Podcast Description: Shahad Abdulsahib discusses a recent Phase 1 clinical trial on Rhenium-186 nanoliposome therapy for recurrent glioma, published in Nature Communications in March 2025.

Probiotics. They are often marketed as the end of all and be all for all our health issues. And they CAN do some real good. There is NO DOUBT a connection with overall heath and gut health…and NO ONE can deny that. But probiotics gets grey for some women's health issues. A new prospective, single-arm, non-blinded, multicenter study across 31 hospitals in Japan is making some pretty dramatic claims regarding oral probiotics and recurrent spontaneous preterm birth (ePUB). Can oral probiotics reduce spontaneous recurrent preterm birth? Listen in for details. 1. Prevention of Recurrent Spontaneous Preterm Delivery Using Probiotics: Results from a Prospective, Single-Arm, Multicenter Trial. PPP trial Collaborators et al.American Journal of Obstetrics & Gynecology, Volume 0, Issue 02. Grev J, Berg M, Soll R. Maternal probiotic supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2018 Dec 12;12(12):CD012519. doi: 10.1002/14651858.CD012519.pub2. PMID: 30548483; PMCID: PMC6516999.3. Jarde A, Lewis-Mikhael AM, Moayyedi P, Stearns JC, Collins SM, Beyene J, McDonald SD. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2018 Jan 8;18(1):14. doi: 10.1186/s12884-017-1629-5. PMID: 29310610; PMCID: PMC5759212.4. Othman M, Neilson JP, Alfirevic Z. Probiotics for preventing preterm labour. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD005941. doi: 10.1002/14651858.CD005941.pub2. PMID: 17253567; PMCID: PMC9006117.5. Timing of Probiotic Milk Consumption During Pregnancy and Effects on the Incidence of Preeclampsia and Preterm Delivery: A Prospective Observational Cohort Study in Norway.6. Nordqvist M, Jacobsson B, Brantsæter AL, Myhre R, Nilsson S, Sengpiel V. Timing of probiotic milk consumption during pregnancy and effects on the incidence of preeclampsia and preterm delivery: a prospective observational cohort study in Norway. BMJ Open. 2018 Jan 23;8(1):e018021. doi: 10.1136/bmjopen-2017-018021. PMID: 29362253; PMCID: PMC5780685.7. Gao Q, Sun Y, Qu Y, Li F, Li P. The effect of probiotic supplementation during pregnancy on pregnancy complications: An umbrella meta-analysis. Medicine (Baltimore). 2025 Dec 19;104(51):e46409. doi: 10.1097/MD.0000000000046409. PMID: 41430994; PMCID: PMC12727282.SPONSOR WEBSITE: Visit perspectivemedical.org to learn more about the Hemorrhage View C-Section Drape

In this episode of Optimal Metabolism, I sit down with Dr. Michael Biamonte, founder of the Biamonte Center for Clinical Nutrition and author of The Candida Chronicles, to unpack the surprising connection between Candida overgrowth and metabolic dysfunction. Candida is often reduced to "just a yeast infection," but Dr. Biamonte explains why chronic fungal overgrowth can disrupt insulin signaling, impair liver detoxification, drive inflammation, weaken immunity, and create the perfect storm for weight gain, fatigue, high cholesterol, and blood pressure issues. If you've ever felt like your body is working against you, this conversation may connect the dots. You may want to explore this deeper if you experience: Stubborn weight loss resistance Blood sugar swings or insulin resistance Chronic fatigue or brain fog Recurrent infections Bloating, digestive complaints, or food sensitivities Hormonal imbalances that don't improve with diet alone

Today, we're bringing you a special feed drop from ReCurrent, a podcast from the Getty that explores how art, history, and culture shape the world around us. In this episode of ReCurrent, host Jaime Roque takes us back to 1980s Los Angeles, when civil wars in El Salvador, Guatemala, and Nicaragua sent hundreds of thousands of people north and helped turn LA into “Little Central America.” With professor and longtime participant Rubén Martínez as our guide—someone who lived through this moment firsthand—we follow the Sanctuary Movement as churches quietly, and then publicly, open their doors to refugees the U.S. refused to recognize. Sanctuary meant food and a place to sleep, but it also meant music, theater, poetry, and posters that challenged U.S. policy while helping people process their grief. From there, we step inside Echo Park United Methodist Church, where artist and performer Elia Arce and a circle of Central American poets, musicians, and organizers transform the basement into a cultural home. We also sit with Rev. David Farley, pastor emeritus of Echo Park United Methodist, who was there to witness it all. Upstairs, families try to stay invisible on classroom floors; downstairs, performances inspired by banned writers, songs from back home, and handmade banners turn fear and exile into shared story. Our last stop is the Getty Research Institute, where researcher Jasmine Magaña—a Salvadoran Angeleno herself—is helping build a new, expansive record of this era.  Learn more about the episode here: https://www.getty.edu/podcasts/recurrent/central-american-art-and-resistance-in-1980s-la/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Recurrent respiratory papillomatosis (RRP) has long been managed with repeated surgical debulking, sometimes requiring dozens of procedures over a lifetime. In this episode of BackTable, Dr. Aaron Friedman and guest host Dr. Stephen Schoeff discuss a major shift in care: immune-directed therapy targeting HPV 6 and 11. --- SYNPOSIS Dr. Friedman reviews the recent FDA approval of the Precigen product PAPZIMEOS (August 2025), a therapeutic vaccine designed to stimulate HPV-specific T-cell responses. Clinical trial data show that about half of treated adults required no additional surgeries over the following year, with many responders maintaining durable benefit for years. The conversation also covers traditional management strategies, adjuvant therapies like bevacizumab, HPV vaccination, and the evolving algorithm for adult RRP care. --- TIMESTAMPS 00:00 - Introduction02:13 - RRP Patient Types and Symptoms05:06 - Adult vs Juvenile Transmission10:46 - When to Escalate Treatment15:40 - Immunotherapy 18:55 - Trial Enrollment, Results and Dosing Rules26:17 - Durable Long Term Response30:47 - Who Should Get Treated32:34 - Logistics And Public Perception37:50 - Future Research And Prevention --- Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRPhttps://pubmed.ncbi.nlm.nih.gov/41543033/ Dr. Stephen Schoeffhttps://healthy.kaiserpermanente.org/washington/clinicians/stephen-schoeff-6848607 Dr. Aaron Friedman https://www.uchealth.com/en/provider-profiles/friedman-aaron-d-1609057587

With over a billion creators projected to be active in the next decade, is the traditional distinction between a brand, a publisher, and a creator in need of an updated definition?Agility requires not just reacting to new platforms, but fundamentally rethinking who creates your content and how you build an authentic community around it. It's about moving from a campaign mindset to an ecosystem mindset.Today, we're going to talk about the seismic shift in the media landscape, driven by the explosive growth of the creator economy. We'll explore how the very definition of a creator is evolving from a short-term influencer to a long-term brand builder, and what opportunities and challenges this presents for established brands that are trying to earn and keep their audience's attention.To help me discuss this topic, I'd like to welcome, Andrew Perlman, Co-Founder and CEO at Recurrent. About Andrew Perlman Andrew Perlman is the Co-Founder and Chief Executive Officer of Recurrent. Perlman co-founded the company in 2018 with the acquisition of The Drive. Over a span of three years, he oversaw the acquisition of nearly 25 noteworthy brands, including Task & Purpose, Popular Science, Dwell, and Donut, and in the process, introduced Recurrent as the new parent company for the digital media portfolio. In 2022, Perlman rejoined the organization from his role on the board as the Head of M&A and Corporate Development before he assumed the role of CEO in 2023. Previously, Andrew spent over six years as the Chief Executive Officer of XpresSpa, FORM Holdings, and its predecessor company, Vringo, where he led the overall business operations and strategy as well as capital raising. During his tenure, he also oversaw five acquisitions and the NASDAQ listing of the company. Andrew has also served as Vice President of Business Development at EMI Music, SVP of Music and Digital at Classic Media, and held roles at early mobile content companies. Andrew Perlman on LinkedIn: https://www.linkedin.com/in/adperlman/ Resources Recurrent: https://recurrent.io/ Take your personal data back with Incogni! Use code AGILE at the link below and get 60% off an annual plan: https://aglbrnd.co/r/c43e68ce5cfb321e The Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://aglbrnd.co/r/2868abd8085a9703 Drive your customers to new horizons at the premier retail event of the year for Retail and Brand marketers. Learn more at CRMC 2026, June 1-3. https://aglbrnd.co/r/d15ec37a537c0d74 Enjoyed the show? Tell us more at and give us a rating so others can find the show at: https://aglbrnd.co/r/faaed112fc9887f3 Connect with Greg on LinkedIn: https://www.linkedin.com/in/gregkihlstromDon't miss a thing: get the latest episodes, sign up for our newsletter and more: https://aglbrnd.co/r/35ded3ccfb6716ba Check out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology: https://www.agilebrandguide.com The Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. https://www.missinglink.company Hosted on Acast. See acast.com/privacy for more information.

With over a billion creators projected to be active in the next decade, is the traditional distinction between a brand, a publisher, and a creator in need of an updated definition? Agility requires not just reacting to new platforms, but fundamentally rethinking who creates your content and how you build an authentic community around it. It's about moving from a campaign mindset to an ecosystem mindset. Today, we're going to talk about the seismic shift in the media landscape, driven by the explosive growth of the creator economy. We'll explore how the very definition of a creator is evolving from a short-term influencer to a long-term brand builder, and what opportunities and challenges this presents for established brands that are trying to earn and keep their audience's attention. To help me discuss this topic, I'd like to welcome, Andrew Perlman, Co-Founder and CEO at Recurrent. About Andrew Perlman Andrew Perlman is the Co-Founder and Chief Executive Officer of Recurrent. Perlman co-founded the company in 2018 with the acquisition of The Drive. Over a span of three years, he oversaw the acquisition of nearly 25 noteworthy brands, including Task & Purpose, Popular Science, Dwell, and Donut, and in the process, introduced Recurrent as the new parent company for the digital media portfolio. In 2022, Perlman rejoined the organization from his role on the board as the Head of M&A and Corporate Development before he assumed the role of CEO in 2023. Previously, Andrew spent over six years as the Chief Executive Officer of XpresSpa, FORM Holdings, and its predecessor company, Vringo, where he led the overall business operations and strategy as well as capital raising. During his tenure, he also oversaw five acquisitions and the NASDAQ listing of the company. Andrew has also served as Vice President of Business Development at EMI Music, SVP of Music and Digital at Classic Media, and held roles at early mobile content companies. Andrew Perlman on LinkedIn: https://www.linkedin.com/in/adperlman/ Resources Recurrent: https://recurrent.io/ Take your personal data back with Incogni! Use code AGILE at the link below and get 60% off an annual plan: https://aglbrnd.co/r/c43e68ce5cfb321e The Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://aglbrnd.co/r/2868abd8085a9703 Drive your customers to new horizons at the premier retail event of the year for Retail and Brand marketers. Learn more at CRMC 2026, June 1-3. https://aglbrnd.co/r/d15ec37a537c0d74 Enjoyed the show? Tell us more at and give us a rating so others can find the show at: https://aglbrnd.co/r/faaed112fc9887f3 Connect with Greg on LinkedIn: https://www.linkedin.com/in/gregkihlstromDon't miss a thing: get the latest episodes, sign up for our newsletter and more: https://aglbrnd.co/r/35ded3ccfb6716ba Check out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology: https://www.agilebrandguide.com The Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. https://www.missinglink.company

Trigger Warning - Pregnancy after loss. In this episode, Alex returns to the podcast (last seen S8 E16) to talk openly about life after loss. She shares her experience of recurrent miscarriages and what it was really like to step back into pregnancy carrying grief, fear, and hope all at the same time.Alex reflects on the emotional toll of trying again - the constant worry, the anxiety that never quite switches off, and the careful ways she learned to protect herself while still allowing room for hope. She speaks honestly about the coping strategies that helped her get through the hardest moments, and how vital support from others was when everything felt overwhelming.This conversation is a reminder that pregnancy after loss is rarely straightforward. It's about finding balance, holding onto small positives, and allowing yourself to feel everything - without guilt or expectation.

343: Today I'm joined by Dr. Albert Chung, who is a certified colon and rectal surgeon specializing in hemorrhoids, colorectal cancer, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Anal Fissures and more. In our interview, we hone in on the topic of hemorrhoids and discuss what they are, natural ways to treat them and prevent them, and what we've been doing wrong!  Topics Discussed: → Different types of hemorrhoids → What causes hemorrhoids → What to look for if you have one → When to see a doctor → Typical time it takes for them to go away → Home treatments and what NOT to do → Is surgery for everyone → Different types of surgery options → Surgery recovery time  → What to expect from surgery → How to prevent hemorrhoids  As always, if you have any questions for the show please email us at digestthispod@gmail.com. And if you like this show, please share it, rate it, review it and subscribe to it on your favorite podcast app.  Sponsored By:  → Fatty15 | For 15% off the starter kit go to https://fatty15.com/digest → Seven Sundays | Go to https://sevensundays.com/ and use code: lilsip for 20% off Timestamps: → 00:00:00 - Introduction  → 00:02:36 - What are hemorrhoids  → 00:07:10 - Stress & digestion  → 00:09:12 - Sitting too long on the toilet  → 00:10:46 - Office chair donuts  → 00:12:06 - Hemorrhoid treatments  → 00:16:14 - Fiber intake  → 00:20:31 - Hydration level  → 00:23:18 - Size range  → 00:24:35 - When to see a doctor  → 00:26:17 - Recovery time→ 00:29:09 - Hemorrhoid surgery & recovery  → 00:33:43 - Pain management & level → 00:36:35 - Surgery options  → 00:39:03 - Recurrent hemorrhoids  → 00:41:11 - Untreated hemorrhoids  → 00:43:12 - Hemorrhoid prevention  Check Out Dr. Chung: → YouTube: Your Friendly Proctologist | @yourfriendlyproctologist → Instagram: @YourFriendlyProctologist  | https://www.instagram.com/yourfriendlyproctologist/ → Website | https://crsurgeryoc.com  Check Out Bethany: → Bethany's Instagram: @lilsipper → YouTube → Bethany's Website → Discounts & My Favorite Products → My Digestive Support Protein Powder → Gut Reset Book  → Get my Newsletters (Friday Finds) Learn more about your ad choices. Visit megaphone.fm/adchoices

If you've been told your embryos look good, your lining is appropriate, and your hormones are in range, yet implantation keeps failing, it can leave you with a nagging feeling that something is missing, but you can't quite put your finger on it. Most couples don't repeat IVF or transfers casually. They follow the plan that's laid out, adjust protocols, and keep moving forward because that's what makes sense. When outcomes don't change, the explanation often shifts to chance, timing, or trying again. In this episode, we talk about why those explanations often feel unsatisfying, and why implantation failure can persist even when everything looks reasonable on paper. Not because you haven't done enough, but because the full picture may never have been looked at all at once. This conversation is about stepping back and asking better questions before moving forward again. In this episode, we explore: Why "good embryos" and "normal labs" don't always translate into implantation How focusing on individual results can miss what's happening across the whole system Why changing protocols doesn't always address repeat outcomes The kinds of patterns that tend to go unexplored when everything looks fine How to think more clearly about whether another cycle is actually the next step Rather than offering another checklist or protocol, this episode helps you zoom out and understand why implantation is rarely a single-factor issue. I'm Sarah Clark, founder of Fab Fertile and host of Get Pregnant Naturally. For over a decade, my team and I have reviewed hundreds of low AMH and failed IVF cases using functional testing alongside conventional fertility care. We specialize in helping couples identify the physiological patterns driving poor outcomes so decisions are grounded in interpretation, not guesswork. If you've been moving from cycle to cycle without a clear way to evaluate what's actually been addressed, I created a free resource called the Embryo Audit Checklist. It helps you organize past cycles and labs so you can see what's been looked at and what may not have been considered yet. Access it here.

On this, our 304th Evolutionary Lens livestream, we discuss the mainstream media's pivot, in which they now tentatively accept that some children have died from the mRNA Covid shots. We discuss failing trust in science, why it will not be quick to fix the institutions or to people them with honest scientists, and the rebels in the hills who are keeping the flame alive. Also, the application of the phrase “safe and effective” to products that are neither. Then: hominids have been making and controlling fire for far longer than we had thought. And: hadrosaurid dinosaurs were, perhaps, quite clumsy at sex.*****Our sponsors:Caraway: Non-toxic, highly functional & beautiful cookware and bakeware. http://Carawayhome.com/DH10 to for up to 25% off your next purchase.Masa Chips: Delicious chips made with corn, salt, and beef tallow—nothing else—in loads of great flavors. Go to http://masachips.com/DarkHorse, use code DarkHorse, for 20% off.CrowdHealth: Pay for healthcare with crowdfunding instead of insurance. It's way better. Use code DarkHorse at http://JoinCrowdHealth.com to get 1st 3 months for $99/month.*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org*****Mentioned in this episode:The Atlantic: Yes, Some Children May Have Died From COVID Shots: https://www.theatlantic.com/health/2025/12/prasad-memo-covid-vaccine-deaths/685175/Myocarditis and mRNA shots in Science Translational Medicine: https://www.science.org/doi/10.1126/scitranslmed.adq0143Earliest evidence of making fire: SciAm links to original research: https://www.scientificamerican.com/article/ancient-humans-were-making-fire-350-000-years-earlier-than-scientists/Recurrent pattern of tail injuries in hadrosaurid dinosaurs: https://www.cell.com/iscience/pdf/S2589-0042(25)02000-0.pdfSupport the show